Indivior Pharmaceuticals, Inc. INDV Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $317M+19.2% | $358M+19.7% | $314M+2.3% | $302M+1.0% | $266M-6.3% | ||
| $40M-9.1% | $67M+39.6% | $83M+25.8% | $52M-34.2% | $44M+15.8% | ||
| $277M+24.8% | $291M+15.9% | $231M-4.1% | $250M+13.6% | $222M-9.8% | ||
| 87.4%+3.9pp | 81.3%-2.7pp | 73.6%-4.9pp | 82.8%+9.2pp | 83.5%-3.2pp | ||
| $16M-27.3% | $21M-32.3% | $33M+50.0% | $21M-19.2% | $22M-21.4% | ||
| $124M-6.8% | $189M+8.0% | $155M+9.2% | $158M+3.9% | $133M-7.0% | ||
| $139M-10.9% | —— | $187M-9.2% | —— | $156M-8.8% | ||
| $139M-10.9% | —— | $187M-9.2% | —— | $156M-8.8% | ||
| $137M+108% | $81M+76.1% | $43M+22.9% | $72M+161% | $66M-12.0% | ||
| 43.2%+18.4pp | 22.6%+7.2pp | 13.7%+2.3pp | 23.8%+63.3pp | 24.8%-1.6pp | ||
| $7M-41.7% | $6M-53.8% | $12M+9.1% | $15M+66.7% | $12M+33.3% | ||
| $3M-25.0% | $6M+20.0% | $6M+20.0% | $6M0.0% | $4M-42.9% | ||
| -$18M— | —— | —— | —— | $0— | ||
| $115M+94.9% | $81M+113% | $37M+23.3% | $62M+151% | $59M-19.2% | ||
| $26M+136% | —— | -$5M-163% | $44M+291% | $11M0.0% | ||
| $89M+89.4% | $102M+386% | $42M+90.9% | $18M+119% | $47M-23.0% | ||
| 28.1%+10.4pp | 28.5%+21.5pp | 13.4%+6.2pp | 6%+38.4pp | 17.7%-3.8pp | ||
| $0.69+81.6% | $0.79+394% | $0.33+106% | $0.14+119% | $0.38-15.6% | ||
| $0.71+86.8% | $0.81+406% | $0.34+113% | $0.15+121% | $0.38-15.6% | ||
| 129M+3.2% | 128M-3.8% | 129M-3.0% | 126M-6.7% | 125M-8.8% | ||
| 124M0.0% | 125M-5.3% | 125M-5.3% | 125M-7.4% | 124M-8.8% | ||
| $16M-27.3% | $21M-32.3% | $33M+50.0% | $21M-19.2% | $22M-21.4% | ||
| $317M+19.2% | $358M+19.7% | $314M+2.3% | $302M+1.0% | $266M-6.3% | ||
| $137M+108% | $81M+76.1% | $43M+22.9% | $72M+161% | $66M-12.0% | ||
| $139M+101% | $83M+62.7% | $46M+17.9% | $74M+164% | $69M-13.8% | ||
| $139M+101% | $83M+62.7% | $46M+17.9% | $74M+164% | $69M-13.8% | ||
| 43.8%+17.9pp | 23.2%+6.1pp | 14.6%+1.9pp | 24.5%+63.3pp | 25.9%-2.2pp | ||
| $137M+108% | $81M+76.1% | $43M+22.9% | $72M+161% | $66M-12.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Indivior Pharmaceuticals, Inc. 's profit margins?
- Gross margin is 81.3% and operating margin is 25.8%, with a 19.4% net margin.
- Where does Indivior Pharmaceuticals, Inc. 's income statement data come from?
- Every line is extracted from Indivior Pharmaceuticals, Inc. 's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.